Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Macdonald, S. Smalley, J. Benedetti, S.A Hundhal, N. Estes, G.N Stemmermannn, D. Haller, J. Ajani, L. Gunderson, J. Jessup, J. Martenson (2002)
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.The New England journal of medicine, 345 10
H. Vollmers, F. Hensel, R. Hermann, J. Dämmrich, E. Woźniak, P. Gessner, B. Herrmann, U. Zimmermann, H. Müller-hermelink (1998)
Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer.Oncology reports, 5 1
F. Hensel, R. Hermann, C. Schubert, N. Abé, K. Schmidt, A. Franke, A. Shevchenko, M. Mann, H. Müller-hermelink, H. Vollmers (1999)
Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis.Cancer research, 59 20
P. Mcculloch, M. Niita, Hussain Kazi, J. Gama-Rodrigues (2005)
Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancerBritish Journal of Surgery, 92
H. Vollmers, J. Dámmrich, H. Ribbert, E. Woźniak, H. Müller-hermelink (1995)
Apoptosis of stomach carcinoma cells induced by a human monoclonal antibodyCancer, 76
Yoong (2011)
Targeted therapies for gastric cancer: current statusDrugs, 71
Macdonald (2001)
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med, 345
K. Becker, R. Langer, D. Reim, A. Novotny, Christian Buschenfelde, J. Engel, H. Friess, H. Hofler (2011)
Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 CasesAnnals of Surgery, 253
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)
Global cancer statisticsCA: A Cancer Journal for Clinicians, 61
M. Shah, R. Ramanathan, D. Ilson, Alissa Levnor, D. D’Adamo, E. O’Reilly, A. Tse, R. Trocola, L. Schwartz, M. Capanu, G. Schwartz, D. Kelsen (2006)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 33
M. Heiss, Erich Simon, B. Beyer, K. Gruetzner, A. Tarabichi, R. Babic, F. Schildberg, H. Allgayer (2002)
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 8
S. Smalley, J. Benedetti, D. Haller, S. Hundahl, N. Estes, J. Ajani, L. Gunderson, B. Goldman, J. Martenson, J. Jessup, G. Stemmermann, C. Blanke, J. Macdonald (2012)
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 19
L. Fornaro, M. Lucchesi, C. Caparello, E. Vasile, S. Caponi, L. Ginocchi, G. Masi, A. Falcone (2011)
Anti-HER agents in gastric cancer: from bench to bedsideNature Reviews Gastroenterology &Hepatology, 8
S. Braun, K. Pantel, P. Müller, W. Janni, F. Hepp, C. Kentenich, Stephan Gastroph, Artur Wischnik, T. Dimpfl, Günter Kindermann, G. Riethmüller, G. Schlimok (2000)
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.The New England journal of medicine, 342 8
B. Illert, C. Otto, H. Vollmers, F. Hensel, A. Thiede, W. Timmermann (2005)
Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer.Oncology reports, 13 4
J. Kulig, P. Kolodziejczyk, P. Kulig, J. Legutko (2013)
Targeted therapy for gastric cancer—current statusJournal of Oncology Pharmacy Practice, 19
J. Siewert, K. Böttcher, H. Stein, J. Roder, M. Brennan, H. Wanebo, T. Demeester (1998)
Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study.Annals of surgery, 228 4
H. Vollmers, J. Dämmrich, F. Hensel, H. Ribbert, A. Meyer‐Bahlburg, Tobias Ufken‐Gaul, Marlene Korff, H. Müller-hermelink (1997)
Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinomaCancer, 79
F. Vita, L. Vecchione, G. Galizia, N. Martino, T. Fabozzi, G. Catalano, F. Ciardiello, M. Orditura (2010)
Perspectives in Adjuvant Therapy of Gastric CancerOncology, 77
Vollmers Hp, R. O’Connor, J. Müller, T. Kirchner, H. Müller-hermelink (1989)
SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells.Cancer research, 49 9
B. Illert, M. Fein, C. Otto, F. Cording, D. Stehle, A. Thiede, W. Timmermann (2005)
Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosisScandinavian Journal of Gastroenterology, 40
D. Cunningham, W. Allum, S. Stenning, J. Thompson, C. Velde, M. Nicolson, J. Scarffe, F. Lofts, S. Falk, T. Iveson, David Smith, R. Langley, M. Verma, S. Weeden, Y. Chua, MAGIC Participants (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.The New England journal of medicine, 355 1
W. Allard, J. Matera, M. Miller, M. Repollet, M. Connelly, C. Rao, A. Tibbe, J. Uhr, L. Terstappen (2004)
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 10
H. Vollmers, U. Zimmermann, V. Krenn, W. Timmermann, B. Illert, F. Hensel, R. Hermann, A. Thiede, M. Wilhelm, H. Rückle-Lanz, L. Reindl, H. Müller-hermelink (1998)
Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results.Oncology reports, 5 3
B. Illert, C. Otto, Stephanie Braendlein, A. Thiede, W. Timmermann (2003)
Optimization of a metastasizing human gastric cancer model in nude miceMicrosurgery, 23
J. Meza-Junco, M. Sawyer (2012)
Metastatic gastric cancer – focus on targeted therapiesBiologics : Targets & Therapy, 6
U. Beutner, U. Lorenz, B. Illert, Loretta Rott, W. Timmermann, H. Vollmers, H. Müller-hermelink, A. Thiede, K. Ulrichs (2008)
Neoadjuvant therapy of gastric cancer with the human monoclonal IgM antibody SC-1: impact on the immune system.Oncology reports, 19 3
S. Braun, F. Vogl, B. Naume, W. Janni, Michael Osborne, R. Coombes, G. Schlimok, I. Diel, B. Gerber, G. Gebauer, J. Pierga, C. Marth, D. Oruzio, G. Wiedswang, E. Solomayer, G. Kundt, B. Strobl, T. Fehm, G. Wong, J. Bliss, A. Vincent-Salomon, K. Pantel (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer.The New England journal of medicine, 353 8
H. Hartgrink, C. Velde (2005)
Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancerJournal of Surgical Oncology, 90
The fully human monoclonal antibody PAT-SC1 is specific for an isoform of CD55 (decay-accelerating factor) designated CD55PAT-SC1. This antigen is expressed in the majority (80%) of gastric cancers (GCs), and the antibody induces tumour cell-specific apoptosis in vitro as well as in vivo. PAT-SC1, therefore, has been deemed promising as a therapeutic agent. Here, we describe the results of an academic clinical study performed in a neoadjuvant setting with resectable GC patients. Patients undergoing treatment for GC between 1997 and 2001 were tested for CD55PAT-SC1 expression. Fifty-one resectable patients that tested positively received a single administration of 20 mg PAT-SC1 48 h prior to surgery. They underwent standard surgery with either subtotal or total gastrectomy with bursectomy, omentectomy and a modified D2-lymphadenectomy, aimed at R0 resection. Primary endpoints of the present study were to evaluate side-effects of the PAT-SC1 antibody treatment and to evaluate histopathological effects such as tumour regression and induction of apoptosis. Long-term survival was a secondary endpoint. Administration of PAT-SC1 appeared safe with only reversible side-effects according to WHO grade I and II. Despite the low‑dose of the antibody, 81.6% of the patients showed signs of increased apoptosis within the primary tumour and 60% showed signs of tumour cell regression. Comparison of the 10-year survival rates of the R0-resected CD55PAT-SC1-positive patients treated with the PAT-SC1 antibody with a historical collective of R0-resected CD55PAT-SC1-positive patients not treated with PAT-SC1 indicated a survival benefit in the treated patients. Furthermore, comparison of the patient survival of CD55PAT‑SC1-positive vs. CD55PAT-SC1-negative groups suggested that CD55PAT-SC1 antigen expression is an independent predictor of poor survival in a Cox regression analysis. Antibody PAT-SC1 may be a useful additive therapeutic agent in the treatment of patients with CD55PAT-SC1-expressing GCs. In combination with radical standard surgery, PAT-SC1 given as an adjuvant or neoadjuvant immunotherapeutic agent induces apoptosis in tumour cells which may improve survival of these patients. Because of the human origin and its specific binding to the CD55PAT-SC1 antigen, PAT-SC1 was well tolerated in this trial.
Oncology Reports – Spandidos Publications
Published: Mar 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.